{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:37:48Z","timestamp":1790807868873,"version":"4.1.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>C3 glomerulopathy and idiopathic Ig-associated membranoproliferative GN are kidney diseases characterized by abnormal glomerular complement C3 deposition. These conditions are heterogeneous in outcome, but approximately 50% of patients develop kidney failure within 10 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>To improve identification of patients with poor prognosis, we performed a detailed analysis of percutaneous kidney biopsies in a large cohort of patients. Using a validated histologic scoring system, we analyzed 156 native diagnostic kidney biopsies from a retrospective cohort of 123 patients with C3 glomerulopathy and 33 patients with Ig-associated membranoproliferative GN. We used linear regression, survival analysis, and Cox proportional hazards models to assess the relationship between histologic and clinical parameters with outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Frequent biopsy features were mesangial expansion and hypercellularity, glomerular basement membrane double contours, and endocapillary hypercellularity. Multivariable analysis showed negative associations between eGFR and crescents, interstitial inflammation, and interstitial fibrosis\/tubular atrophy. Proteinuria positively associated with endocapillary hypercellularity and glomerular basement membrane double contours. Analysis of second native biopsies did not demonstrate associations between immunosuppression treatment and improvement in histology. Using a composite outcome, risk of progression to kidney failure associated with eGFR and proteinuria at the time of biopsy, cellular\/fibrocellular crescents, segmental sclerosis, and interstitial fibrosis\/tubular atrophy scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our detailed assessment of kidney biopsy data indicated that cellular\/fibrocellular crescents and interstitial fibrosis\/tubular atrophy scores were significant determinants of deterioration in kidney function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.16801221","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T10:55:14Z","timestamp":1656672914000},"page":"994-1007","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":51,"title":["Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis"],"prefix":"10.2215","volume":"17","author":[{"given":"Hannah J.","family":"Lomax-Browne","sequence":"first","affiliation":[{"name":"Department for Immunology and Inflammation, Centre for Inflammatory Disease, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas R.","family":"Medjeral-Thomas","sequence":"additional","affiliation":[{"name":"Department for Immunology and Inflammation, Centre for Inflammatory Disease, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J.","family":"Barbour","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0511-8123","authenticated-orcid":false,"given":"Jack","family":"Gisby","sequence":"additional","affiliation":[{"name":"Department for Immunology and Inflammation, Centre for Inflammatory Disease, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heedeok","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Bomback","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9952-209X","authenticated-orcid":false,"given":"Fernando C.","family":"Fervenza","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Cairns","sequence":"additional","affiliation":[{"name":"West London Renal and Transplant Centre, Imperial College Healthcare NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Szydlo","sequence":"additional","affiliation":[{"name":"Department for Immunology and Inflammation, Centre for Haematology, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven-Jean","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Royal Melbourne Hospital, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9850-8352","authenticated-orcid":false,"given":"Stephen D.","family":"Marks","sequence":"additional","affiliation":[{"name":"Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom"},{"name":"National Institute for Health Research Great Ormond Street Hospital Biomedical Research Centre, University College London Great Ormond Street Institute of Child Health, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoife M.","family":"Waters","sequence":"additional","affiliation":[{"name":"Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald B.","family":"Appel","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivette D.","family":"D\u2019Agati","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4536-7709","authenticated-orcid":false,"given":"Sanjeev","family":"Sethi","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia C.","family":"Nast","sequence":"additional","affiliation":[{"name":"Department of Pathology, Cedars-Sinai Medical Center, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg","family":"Bajema","sequence":"additional","affiliation":[{"name":"Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Alpers","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes B.","family":"Fogo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Licht","sequence":"additional","affiliation":[{"name":"Division of Nephrology, The Hospital for Sick Children, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Fakhouri","sequence":"additional","affiliation":[{"name":"Service of Nephrology and Hypertension, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Cattran","sequence":"additional","affiliation":[{"name":"Toronto General Research Institute, Division of Nephrology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Peters","sequence":"additional","affiliation":[{"name":"Department for Immunology and Inflammation, Centre for Inflammatory Disease, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Terence","family":"Cook","sequence":"additional","affiliation":[{"name":"Department for Immunology and Inflammation, Centre for Inflammatory Disease, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1153-0192","authenticated-orcid":false,"given":"Matthew C.","family":"Pickering","sequence":"additional","affiliation":[{"name":"Department for Immunology and Inflammation, Centre for Inflammatory Disease, Imperial College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,7]]},"reference":[{"key":"B1-20241015","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ki.2013.377","article-title":"C3 glomerulopathy: Consensus report","volume":"84","author":"Pickering","year":"2013","journal-title":"Kidney Int"},{"key":"B2-20241015","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/nrneph.2014.217","article-title":"Histopathology of MPGN and C3 glomerulopathies","volume":"11","author":"Cook","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"B3-20241015","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/ki.1986.278","article-title":"H deficiency in two brothers with atypical dense intramembranous deposit disease","volume":"30","author":"Levy","year":"1986","journal-title":"Kidney Int"},{"key":"B4-20241015","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/sj.ki.5000269","article-title":"Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II)","volume":"70","author":"Licht","year":"2006","journal-title":"Kidney Int"},{"key":"B5-20241015","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.4049\/jimmunol.163.8.4590","article-title":"Nephritogenic lambda light chain dimer: A unique human miniautoantibody against complement factor H","volume":"163","author":"Jokiranta","year":"1999","journal-title":"J Immunol"},{"key":"B6-20241015","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3389\/fimmu.2019.00886","article-title":"Nephritic factors: An overview of classification, diagnostic tools and clinical associations","volume":"10","author":"Corvillo","year":"2019","journal-title":"Front Immunol"},{"key":"B7-20241015","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.kint.2017.04.017","article-title":"C5 nephritic factors drive the biological phenotype of C3 glomerulopathies","volume":"92","author":"Marinozzi","year":"2017","journal-title":"Kidney Int"},{"key":"B8-20241015","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int"},{"key":"B9-20241015","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.molimm.2016.01.010","article-title":"Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome","volume":"71","author":"Iatropoulos","year":"2016","journal-title":"Mol Immunol"},{"key":"B10-20241015","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.kint.2017.10.022","article-title":"C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy","volume":"93","author":"Bomback","year":"2018","journal-title":"Kidney Int"},{"key":"B11-20241015","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2215\/CJN.04700513","article-title":"C3 glomerulopathy: Clinicopathologic features and predictors of outcome","volume":"9","author":"Medjeral-Thomas","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"B12-20241015","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1681\/ASN.2007030356","article-title":"New approaches to the treatment of dense deposit disease","volume":"18","author":"Smith","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"B13-20241015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy - understanding a rare complement-driven renal disease","volume":"15","author":"Smith","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B14-20241015","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2215\/CJN.09080817","article-title":"Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: A case series","volume":"13","author":"Avasare","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"B15-20241015","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1007\/s00467-018-4034-z","article-title":"Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents","volume":"33","author":"Holle","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"B16-20241015","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1093\/ckj\/sfy127","article-title":"Usefulness of mycophenolate mofetil in Indian patients with C3 glomerulopathy","volume":"12","author":"Bharati","year":"2018","journal-title":"Clin Kidney J"},{"key":"B17-20241015","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2215\/CJN.15241219","article-title":"Mycophenolate mofetil in C3 glomerulopathy and pathogenic drivers of the disease","volume":"15","author":"Caravaca-Font\u00e1n","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"B18-20241015","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/ki.2015.227","article-title":"Effectiveness of mycophenolate mofetil in C3 glomerulonephritis","volume":"88","author":"Rabasco","year":"2015","journal-title":"Kidney Int"},{"key":"B19-20241015","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000479012","article-title":"Immunosuppressive treatment in C3 glomerulopathy: Is it really effective?","volume":"46","author":"Caliskan","year":"2017","journal-title":"Am J Nephrol"},{"key":"B20-20241015","first-page":"15","article-title":"Evaluation of clinical, laboratory and treatment modalities in C3 glomerulopathy: Single center experience","volume":"40","author":"Yeter","year":"2019","journal-title":"Pril (Makedon Akad Nauk Umet Odd Med Nauki)"},{"key":"B21-20241015","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.mayocp.2018.05.019","article-title":"C3 glomerulopathy: Ten years\u2019 experience at Mayo Clinic","volume":"93","author":"Ravindran","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"B22-20241015","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood-2016-08-737163","article-title":"Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy","volume":"129","author":"Chauvet","year":"2017","journal-title":"Blood"},{"key":"B23-20241015","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2017.11.019","article-title":"Patterns of clinical response to eculizumab in patients with C3 glomerulopathy","volume":"72","author":"Le Quintrec","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"B24-20241015","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.ekir.2019.06.008","article-title":"Glomerular complement factor H-related protein 5 (FHR5) is highly prevalent in C3 glomerulopathy and associated with renal impairment","volume":"4","author":"Medjeral-Thomas","year":"2019","journal-title":"Kidney Int Rep"},{"key":"B25-20241015","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1053\/j.ajkd.2020.11.011","article-title":"Validation of a histologic scoring index for C3 glomerulopathy","volume":"77","author":"Caravaca-Font\u00e1n","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"B26-20241015","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1093\/ndt\/gfab169","article-title":"Contribution of a histologic index to the prognostic information of C3 glomerulopathy","volume":"36","author":"Caravaca-Font\u00e1n","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"B27-20241015","article-title":"Longitudinal change in proteinuria and kidney outcomes in C3 glomerulopathy","author":"Caravaca-Fontan","journal-title":"Nephrol Dial Transplant"},{"key":"B28-20241015","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.semnephrol.2011.06.005","article-title":"Membranoproliferative glomerulonephritis: Pathogenetic heterogeneity and proposal for a new classification","volume":"31","author":"Sethi","year":"2011","journal-title":"Semin Nephrol"},{"key":"B29-20241015","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.kint.2016.06.020","article-title":"The relatively poor correlation between random and 24-hour urine protein excretion in patients with biopsy-proven glomerular diseases","volume":"90","author":"Hogan","year":"2016","journal-title":"Kidney Int"},{"key":"B30-20241015","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/ndt\/gfv454","article-title":"An estimated glomerular filtration rate equation for the full age spectrum","volume":"31","author":"Pottel","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"B31-20241015","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1007\/s00467-013-2565-x","article-title":"Evolution of immunoglobulin deposition in C3-dominant membranoproliferative glomerulopathy","volume":"28","author":"Kerns","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"B32-20241015","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1681\/ASN.2017030258","article-title":"Cluster analysis identifies distinct pathogenetic patterns in C3 glomerulopathies\/immune complex-mediated membranoproliferative GN","volume":"29","author":"Iatropoulos","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B33-20241015","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamainternmed.2019.0600","article-title":"Evaluating a new international risk-prediction tool in IgA nephropathy","volume":"179","author":"Barbour","year":"2019","journal-title":"JAMA Intern Med"},{"key":"B34-20241015","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ki.2015.322","article-title":"The MEST score provides earlier risk prediction in lgA nephropathy","volume":"89","author":"Barbour","year":"2016","journal-title":"Kidney Int"},{"key":"B35-20241015","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1681\/ASN.2019040433","article-title":"Large-scale whole-genome sequencing reveals the genetic architecture of primary membranoproliferative GN and C3 glomerulopathy","volume":"31","author":"Levine","year":"2020","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.16801221","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:44:50Z","timestamp":1786369490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.16801221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.16801221","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"2021-12-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}